Overview
NUVB market data
Price History
NUVB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.60 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.58 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -88.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.21 – $9.75 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.3B · P/B 10.08 · P/S 13.31.
Company News
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20Benzinga · Aug 7, 2026, 7:58 PM
8-K filing — Nuvation Bio Inc. (NUVB)SEC EDGAR · Aug 6, 2026, 11:30 AM
Nuvation Bio Q2 EPS $(0.18) Beats $(0.19) Estimate, Sales $31.687M Beat $27.505M EstimateBenzinga · Aug 6, 2026, 10:58 AM
Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMOBenzinga · Aug 4, 2026, 12:12 PM
HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21Benzinga · Jul 27, 2026, 12:21 PM
Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price TargetBenzinga · Jul 23, 2026, 2:21 PM
Why Is Nuvation Bio Stock Gaining Monday?Benzinga · Jul 20, 2026, 3:44 PM
AMC Entertainment, IREN, Hut 8 And Other Big Stocks Moving Higher On MondayBenzinga · Jul 20, 2026, 2:08 PM
Nuvation Bio shares are trading higher after the company announced updated long-term follow-up data from the Phase 2 study of safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma.Benzinga · Jul 20, 2026, 2:06 PM
Nuvation Bio Announces Positive Updated Phase 2 Data And Expansion From Safusidenib Clinical Trial In Newly-Diagnosed Grade 2 Glioma Patients Outside The U.S.Benzinga · Jul 20, 2026, 12:09 PM